Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AHCT intensification + teclistamab + daratumumab
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
AHCT intensification + teclistamab + daratumumab is a multi-phase combination treatment regimen evaluated in the MASTER-2 phase 2 clinical trial (NCT05231629) for patients with newly diagnosed multiple myeloma (NDMM). The regimen is specifically utilized for patients who remain minimal residual disease (MRD) positive after induction therapy with daratumumab, bortezomib, lenalidomide, and dexamethasone (Dara-VRd). It consists of autologous hematopoietic cell transplantation (AHCT) using melphalan conditioning as an intensification step, followed by consolidation and maintenance phases using a combination of teclistamab (a BCMA x CD3 bispecific T-cell engager) and daratumumab (a CD38-targeting monoclonal antibody). This MRD-guided approach aims to achieve deep, sustained responses by intensifying therapy in patients with persistent disease after initial induction.
- Other names
- AHCT intensification + Tec-Dara consolidation + Tec-Dara maintenanceDara-TecDara-Tec consolidationDara-Tec maintenanceAHCT + teclistamab + daratumumab
02
Targets
CD38 (Cluster of Differentiation 38)CD3 (T-cell surface glycoprotein CD3)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on AHCT intensification + teclistamab + daratumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AHCT intensification + teclistamab + daratumumab.